Arvinas ARVN Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Program-specific external expense by Product | ||||||
| ARV-102 | $20M-4.8% | $21M+1.0% | $20.8M+2.5% | $20.3M+11.5% | $18.2M+40.0% | |
| ARV-393 | $12.2M+9.9% | $11.1M+12.1% | $9.9M+10.0% | $9M+9.8% | $8.2M+20.6% | |
| ARV-806 | $19.1M+41.5% | $13.5M+51.7% | $8.9M+93.5% | $4.6M+48.4% | $3.1M+34.8% | |
| Bavdegalutamide (ARV-110) | $1.8M-33.3% | $2.7M-32.5% | $4M-37.5% | $6.4M-20.0% | $8M-5.9% | |
| Other programs | $5.4M+20.0% | $4.5M+60.7% | $2.8M+12.0% | $2.5M+47.1% | $1.7M+1,600% | |
| Vepdegestrant ARV-471 | $47.5M-24.2% | $62.7M-5.7% | $66.5M-7.5% | $71.9M-12.2% | $81.9M+6.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Arvinas break its business down?
- Arvinas (ARVN) reports program-specific external expense by product across 6 parts — ARV-102, ARV-393, ARV-806, Bavdegalutamide (ARV-110) and Other programs. Each is extracted from the segment footnotes and tracked over time.
- Where does Arvinas's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Arvinas's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
